Trade Names:Estropipate- Tablets Sodium estrone sulfate 0.625 mg- Tablets Sodium estrone sulfate 1.25 mg- Tablets Sodium estrone sulfate 2.5 mg
Trade Names:Ogen- Tablets Sodium estrone sulfate 0.625 mg- Tablets Sodium estrone sulfate 1.25 mg
Promotes growth and development of female reproductive system and secondary sex characteristics; affects release of ovulation and prevents postpartum breast engorgement; conserves calcium and phosphorous and encourages bone formation; overrides stimulatory effects of testosterone.
Well absorbed from the GI tract.
Largely bound to sex hormone–binding globulin and albumin. Crosses the placenta.
Undergoes first-pass metabolism. Metabolic conversion occurs primarily in the liver but also at local target tissue sites. Also undergoes enterohepatic recirculation.
Metabolized partially by CYP3A4.
A certain portion is excreted into the bile and then reabsorbed from the intestine. Excreted in the urine as conjugates.
Treatment of moderate to severe vasomotor, vulval, and vaginal atrophy symptoms associated with menopause; treatment of hypoestrogenism caused by castration, hypogonadism, or primary ovarian failure.
Active deep vein thrombosis, pulmonary embolism, or history of these conditions; active or recent (ie, within past year) arterial thromboembolic disease (eg, stroke, MI); hypersensitivity to any component of the product; known or suspected estrogen-dependent neoplasia; known or suspected pregnancy; known, suspected, or history of breast cancer; liver dysfunction or disease; undiagnosed abnormal genital bleeding.
Dosage is calculated as estrone sulfate.Vasomotor Symptoms, Vulval and Vaginal AtrophyAdults
PO 0.625 to 5 mg/day given cyclically.Female Hypogonadism, Female Castration, Primary Ovarian FailureAdults
PO 1.25 to 7.5 mg/day for 3 wk, followed by 8- to 10-day drug-free period.
Store below 77°F.
May reduce plasma estrogens, resulting in a decrease in therapeutic effects and changes in uterine bleeding profile.Inhibitors of CYP3A4 (eg, azole antifungal agents [eg, itraconazole, ketoconazole], grapefruit juice, macrolide antibiotics [eg, clarithromycin, erythromycin], ritonavir)
May elevate estrogen plasma levels, resulting in increased adverse reactions.Corticosteroids (eg, prednisone)
Increased pharmacologic and toxicologic effects of corticosteroids may occur.Hydantoins (eg, phenytoin)
Loss of seizure control or decreased estrogenic effects may occur.Thyroid hormones (eg, levothyroxine)
Serum free thyroxine concentrations may be decreased, increasing serum thyrotropin concentrations and the need for thyroid hormone.
Accelerated PT, partial thromboplastin, and platelet aggregation time; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; decreased serum folate concentration; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and betaî“¸thromboglobulin; increased platelet count; increased plasma HDL and HDL 2 cholesterol subfraction concentrations; increased plasminogen antigen and activity; other serumî“¸binding proteins may be elevated (eg, corticosteroidî“¸binding globulin, sex hormone–binding globulin); increased thyroid-binding globulin and total T4; impaired glucose-tolerance; increased triglyceride levels; other plasma proteins may be increased (eg, ceruloplasmin); reduced LDL cholesterol concentrations; reduced response to metyrapone test.
Deep and superficial venous thrombosis; increased BP; MI; pulmonary embolism; stroke; thrombophlebitis.
Changes in libido; chorea; dementia; dizziness; exacerbation of epilepsy; headache; irritability; mental depression; migraine; mood disturbances; nervousness.
Chloasma or melasma; erythema multiforme; erythema nodosum; hemorrhagic eruption; hirsutism; loss of scalp hair; pruritus; rash; urticaria.
Intolerance to contact lenses; retinal vascular thrombosis; steepening of corneal curvature.
Abdominal cramps; bloating; gallbladder disease; nausea; pancreatitis; vomiting.
Abnormal withdrawal bleeding or flow; breakthrough bleeding; breast cancer; breast enlargement, pain, and tenderness; change in amount of cervical secretion; changes in cervical ectropion; changes in vaginal bleeding pattern; dysmenorrhea; endometrial cancer; exacerbation of endometriosis; fibrocystic breast changes; galactorrhea; increase in size of uterine leiomyomata; nipple discharge; ovarian cancer; spotting; vaginal candidiasis; vaginitis.
Cholestatic jaundice; enlargement of hepatic hemangiomas.
Anaphylactic/anaphylactoid reactions; angioedema.
Changes in triglycerides; decrease or increase in weight; exacerbation of diabetes mellitus; hypercalcemia; hypocalcemia; reduced carbohydrate tolerance.
Arthralgia; leg cramps.
Exacerbation of asthma.
Aggravation of porphyria; edema.
WarningsCV and other risks
Do not use estrogens with or without progestins for prevention of CV disease. The Women's Health Initiative (WHI) study reported increased risk of deep vein thrombosis, invasive breast cancer, MI, pulmonary emboli, and stroke in postmenopausal women 50 to 79 yr of age during 5 yr of treatment with oral conjugated estrogens 0.625 mg combined with medroxyprogesterone acetate 2.5 mg compared with placebo.Dementia
A substudy of WHI, the WHI Memory Study, reported increased risk of developing probable dementia in postmenopausal women 65 yr of age and older during 4 yr of treatment with oral conjugated estrogens plus medroxyprogesterone acetate compared with placebo. It is unknown if this finding applies to younger postmenopausal women or women taking estrogen alone.Endometrial cancer
Close clinical surveillance of all women taking estrogens is important. The use of unopposed estrogen in women with intact uteri has been associated with an increased risk of endometrial cancer. Undertake diagnostic measures, including endometrial sampling when indicated, to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Monitor blood pressure at regular intervals.
Category X .
Excreted in breast milk.
Safety and efficacy not established.
Metabolism may be impaired; use drug with caution.
Long-term continuous administration of estrogen has shown an increased risk of breast, endometrial, and ovarian cancer.
May be exacerbated.
Use drug with careful observation when conditions that might be affected by this factor are present (eg, asthma, cardiac dysfunction, renal function impairment, epilepsy).
Risk of gallbladder disease may increase in women receiving postmenopausal estrogens.
Use with caution in patients with severe hypocalcemia.
Severe hypercalcemia may occur in patients with breast cancer and bone metastases.
Substantial increases in BP have been attributed to idiosyncratic reactions to estrogens.
In patients with preexisting hypertriglyceridemia, estrogen therapy may be associated with plasma triglyceride elevations, leading to pancreatitis and other complications.
May increase risk of endometrial or other carcinomas.
Estrogen plus progestin may increase the risk of ovarian cancer. Data are conflicting as to whether estrogen alone increases the risk of ovarian cancer.
Because estrogens may cause exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, or hepatic hemangiomas, use with caution.
Retinal vascular thrombosis may occur, leading to loss of vision, sudden onset of proptosis, diplopia, or migraine.
Nausea, vomiting, withdrawal bleeding in women.
Copyright © 2009 Wolters Kluwer Health.